Covered recipient · General Payments record
JAMES F SCHAUPP
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$9,141.21
- Reported across 535 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $381.91 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $164.73 | 6 |
| Lilly USA, LLC | $62.14 | 3 |
| GlaxoSmithKline, LLC. | $56.07 | 3 |
| Astellas Pharma US Inc | $53.28 | 2 |
| Esperion Therapeutics, Inc. | $24.28 | 1 |
| Lucid Diagnostics Inc. | $21.41 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $33.08 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031430 | CMS |
| ABBVIE INC. | $22.66 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031432 | CMS |
| ABBVIE INC. | $10.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031434 | CMS |
| ABBVIE INC. | $32.12 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031436 | CMS |
| ABBVIE INC. | $33.05 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031438 | CMS |
| ABBVIE INC. | $33.82 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031440 | CMS |
| Astellas Pharma US Inc | $25.96 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139289302 | CMS |
| Astellas Pharma US Inc | $27.32 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139319586 | CMS |
| Esperion Therapeutics, Inc. | $24.28 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129454074 | CMS |
| GlaxoSmithKline, LLC. | $18.47 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116411507 | CMS |
| GlaxoSmithKline, LLC. | $23.61 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116285228 | CMS |
| GlaxoSmithKline, LLC. | $13.99 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116096920 | CMS |
| Lilly USA, LLC | $20.19 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135039477 | CMS |
| Lilly USA, LLC | $18.44 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135021880 | CMS |
| Lilly USA, LLC | $23.51 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135021878 | CMS |
| Lucid Diagnostics Inc. | $21.41 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152302239 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.